Elixxer Ltd. To Postpone Filing Of Annual Financial Statements And MD&A Due To COVID-19 Related Delays
28 4월 2020 - 6:00AM
Elixxer Ltd. (the “
Corporation” or
“
Elixxer”) (TSX-V: ELXR and OTC-QB: ELIXF)
announces that, due to logistics and delays caused by the COVID-19
pandemic, it will postpone the filing of its annual consolidated
financial statements and related management’s discussion for the
15-month period ended December 31, 2019 (the “
Disclosure
Documents”).
Elixxer is relying on the blanket exemption
provided by the Autorité des marchés financiers and similar
exemptions provided by the other members of the Canadian Securities
Administrators pursuant to which issuers are granted an additional
45 days to complete their regulatory filings. Elixxer
anticipates that its Disclosure Documents will be filed on or about
June 15, 2020. Until such time as the Disclosure Documents
are filed, as required by the conditions of the extension,
Elixxer’s management and other insiders will be subject to a
trading black-out that reflects the principles in Section 9 of
Policy Statement 11-207.
Other than as previously disclosed by Elixxer in
news releases, including the information herein, there are no other
material developments since the date of the Corporation’s most
recent filings of its interim financial statements and related
management’s discussion and analysis for the period ended September
30, 2019. Elixxer will provide an updated news release on the
status of the filing of its Disclosure Documents by May 29,
2020.
About Elixxer Ltd.
(www.elixxer.com)
Elixxer Ltd. is a leading cannabis investment
firm with a focus on the legal global cannabis market. Through its
growing portfolio of investment companies, ELXR is building a
transversal integrated organization of interconnected legal
cannabis companies with cultivation, processing and distribution in
Australia, Jamaica, Switzerland, Italy, and Canada serving domestic
and export markets. Elixxer Ltd. is a Canadian incorporated public
company listed on the TSX Venture Exchange (TSX-V: ELXR) and the US
OTC-QB exchange (OTCQB: ELIXF).
For further information please
contact:
President, John McMullen, +1-416-803-0698,
john@elixxer.com
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
Notice Regarding Forward Looking
Statements
This press release may contain forward-looking
statements with respect to Elixxer and its operations, strategy,
investments, financial performance and condition. These statements
can generally be identified by use of forward-looking words such as
“may”, “will”, “expect”, “estimate”, “anticipate”, “intends”,
“believe” or “continue” or the negative thereof or similar
variations. The actual results and performance of Elixxer could
differ materially from those expressed or implied by such
statements. Such statements are qualified in their entirety by the
inherent risks and uncertainties surrounding future expectations.
Some important factors that could cause actual results to differ
materially from expectations include, among other things, general
economic and market factors, competition, government regulation and
the factors described under “Risk Factors and Risk Management” in
Elixxer’s most recent Management’s Discussion and Analysis filed on
SEDAR (www.sedar.com). The cautionary statements qualify all
forward-looking statements attributable to Elixxer and persons
acting on its behalf. Unless otherwise stated, all forward-looking
statements speak only as of the date of this press release, and
Elixxer has no obligation to update such statements, except to the
extent required by applicable securities laws.
Elixxer (TSXV:ELXR)
과거 데이터 주식 차트
부터 1월(1) 2025 으로 2월(2) 2025
Elixxer (TSXV:ELXR)
과거 데이터 주식 차트
부터 2월(2) 2024 으로 2월(2) 2025